Johnson & Johnson's Tecvayli, Talvey Phase 3 Study in Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival
MT Newswires Live
Jul 23
Johnson & Johnson's (JNJ) phase 3 study evaluating Tecvayli in combination with Talvey and Talvey with pomalidomide in relapsed or refractory multiple myeloma showed improvements in progression-free survival and overall survival for both investigational groups, the drugmaker said Thursday.
Specifically, Tecvayli in combination with Talvey demonstrated a reduction in risk of disease progression or death by 89% and the risk of death by 62%, Johnson & Johnson said.
Based on the data, the independent data monitoring committee has recommended unblinding the study at the first interim analysis, Johnson & Johnson said, adding that it will release full results from the trial at a future major medical meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.